Additional information
| Active substance | Saxagliptin |
|---|---|
| Water Retention | No significant effect on water retention |
| Hepatotoxicity | Low risk of hepatotoxicity |
| Lab Test | Monitoring of hemoglobin A1c levels may be conducted to assess effectiveness |
| Strength | 5mg |
| Also known as | BMS-477118 |
| Blood pressure | Neutral effect on blood pressure |
| Trade name | Onglyza |
| Storage conditions | Store at room temperature, away from moisture and heat |
| Chemical name | (1S,3S,5S)-2-[(2S)-2-Amino-2-(3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile |
| Formula | C18H25N3O2 |
| Substance class | Dipeptidyl peptidase-4 (DPP-4) inhibitor |
| Main action | Lower blood glucose levels by inhibiting the enzyme DPP-4 |
| Half-life | Approximately 2.5 hours |
| Dosage (medical) | Typically 2.5 mg or 5 mg once daily |
| Dosage (sports) | Not applicable |
| Effects | Increases insulin release and decreases glucagon levels in the blood in a glucose-dependent manner |
| Side effects | Upper respiratory tract infection, urinary tract infection, headache, and hypersensitivity reactions such as skin rash and urticaria |
| Use in sports | Not typically used in sports |
| Manufacturer | AstraZeneca Pharma Ltd. |
| Packing | 14 tabs/blister |
Reviews
There are no reviews yet.